Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Starting the New Year and Getting Rid of Type 2 Diabetes?
By Sheri Colberg, PhD
Cost-effectiveness of SGLT2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction
High Deductibles Leading to Reduced Medication Adherence Among Patients with Diabetes
SGLT2is and GLP-1 RAs Show Best Cardiovascular Results when Initiated Sooner
Letter from the Editor
It seems every year we start off our articles with the latest and greatest ways to stick to your resolutions and lose weight, improve your health, and improve your diabetes. Usually that means programs, devices or diets that are either too expensive or too hard to follow. This year, we decided that you should have the knowledge to make your own choices, so we asked our Diabetes Fitness Guru, Dr. Sheri Colberg, to delve into the science of reversing diabetes and provide real proven metabolic research on the value of food choices and physical activity. She is going to share the physiological basis to help your patients.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES — Diabetes News and Research
By Sheri Colberg, PhD
I recently was asked about the latest research on the reversal of type 2 diabetes—both bariatric and non-bariatric solutions—and it made me wonder about the mechanisms of this possibility and what role being active may play in it. Each new year always brings a whole host of resolutions that people make focused on losing weight, getting more fit, and becoming healthier. Especially with all the COVID-related pounds I have heard about people gaining, I expect these resolutions to be out in full force at the start of 2022. But how effective will they be long-term, and is the reversal of type 2 diabetes a realistic resolution to make?
Cost-effectiveness of SGLT2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were created to treat diabetes, but noted to ameliorate cardiovascular events.
Health plans with high deductibles require thousands of dollars out-of-pocket and have a known association with delays in treatment; a repeated cross-sectional study found they are also associated with medication non-adherence.
The case for why an SGLT2 inhibitor or GLP-1 receptor agonist should be initiated early in diabetes treatment, regardless of whether the patient is on insulin therapy.
Artificial intelligence fingerprints gut flora, linking clusters of microbial species with type 1 diabetes development.
DPP4 inhibitors may restore the normal functioning of vascular endothelium in patients who require insulin treatment.
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:
Dalia Elabed, PharmD Candidate 2022, University of South Florida Taneja College of Pharmacy
Oluwatayo Ishola, PharmD. Candidate, South College, School of Pharmacy
Emmanuella Louissaint, PharmD candidate, LECOM College of Pharamacy
Melinda Rodriguez, PharmD Candidate 2021, Lake Erie College of Osteopathic Medicine – L|E|C|O|M School of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com